Related Experiment Videos
Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS)
The American Journal of Cardiology
|May 1, 1997
Insights
Atorvastatin effectively lowers cholesterol and apolipoprotein B levels in a dose-dependent manner. This multicenter study found no serious adverse events, demonstrating atorvastatin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Hyperlipidemia is a significant risk factor for cardiovascular disease.
- Effective lipid-lowering therapies are crucial for managing cardiovascular risk.
Purpose of the Study:
- To evaluate the efficacy and safety of atorvastatin in reducing lipid levels.
- To assess the dose-dependent effects of atorvastatin.
Main Methods:
- A multicenter, placebo-controlled, double-blind study design.
- Inclusion of patients requiring lipid-lowering therapy.
- Administration of varying doses of atorvastatin versus placebo.
Main Results:
- Atorvastatin demonstrated substantial reductions in total cholesterol.
- Significant decreases in low-density lipoprotein cholesterol were observed.
- Apolipoprotein B levels were also dose-dependently reduced.
- No serious adverse events were reported during the study.
Conclusions:
- Atorvastatin is an effective and safe treatment for hyperlipidemia.
- The lipid-lowering effects of atorvastatin are dose-dependent.
- Atorvastatin offers a favorable safety profile for long-term cardiovascular risk management.
Abstract:
A placebo-controlled, double-blind study on the efficacy of atorvastatin was conducted in several multicenters. Atorvastatin reduced total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B substantially in a dose-dependent manner without any serious adverse events.